Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates

Toxicological Sciences

Volumn 139, Issue 1, 2014, Pages 99-107

  Ferslew, Brian C ^a   Brouwer, Kim L R ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANION; AZITHROMYCIN; BILE SALT EXPORT PUMP; CHLOROQUINE; DESIPRAMINE; FAT DROPLET; GENTAMICIN; GLYCOGEN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTING POLYPEPTIDE; POLYPEPTIDE; ROSUVASTATIN; SODIUM BILE ACID COTRANSPORTER; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; FLUOROBENZENE; PHOSPHOLIPID; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BASOLATERAL MEMBRANE; BILIARY CLEARANCE; BILIARY EXCRETION; CONTROLLED STUDY; FLUORESCENCE; LIPIDOSIS; LIVER CELL; LIVER CELL CULTURE; LYSOSOME; LYSOTRACKER RED LOCALIZATION; MALE; MITOCHONDRION; MTT ASSAY; NONHUMAN; RAT; SANDWICH CULTURED HEPATOCYTE; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; HEPATOBILIARY SYSTEM; METABOLISM; TOXICITY; WISTAR RAT;

AMIODARONE; ANIMALS; ANIONS; AZITHROMYCIN; BILIARY TRACT; CELLS, CULTURED; CHLOROQUINE; DESIPRAMINE; FLUOROBENZENES; GENTAMICINS; HEPATOCYTES; MALE; MODELS, BIOLOGICAL; PHOSPHOLIPIDS; PYRIMIDINES; RATS; RATS, WISTAR; SULFONAMIDES; TAUROCHOLIC ACID;

EID: 84922393015     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu033     Document Type: Article

References (41)

1. Abe, K., Bridges, A. S., and Brouwer,K. L. R. (2009).Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab. Dispos. 37, 447-452.
2. Agoston, M., Orsi, F., Feher, E., Hagymasi, K., Orosz, Z., Blazovics, A., Feher, J., and Vereckei, A. (2003). Silymarin and vitamin E reduce amiodaroneinduced lysosomal phospholipidosis in rats. Toxicology 190, 231-241.
3. Annaert, P. P., and Brouwer, K. L. R. (2005). Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 33, 388-394.
4. Atienzar, F., Gerets, H., Dufrane, S., Tilmant, K., Cornet, M.,Dhalluin, S., Ruty, B., Rose, G., and Canning, M. (2007). Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol. Sci. 96, 101-114.
5. Byrne, J. A., Strautnieks, S. S., Mieli-Vergani, G., Higgins, C. F., Linton, K. J., and Thompson, R. J. (2002). The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors. Gastroenterology 123, 1649-1658.
6. Chandra, P., LeCluyse, E. L., and Brouwer, K. L. R. (2001). Optimization of culture conditions for determining hepatobiliary disposition of taurocholate in sandwich-cultured rat hepatocytes. In Vitro Cell. Dev. Biol. Anim. 37, 380-385.
7. Chatman, L. A., Morton, D., Johnson, T. O., and Anway, S. D. (2009). A strategy for risk management of drug-induced phospholipidosis. Toxicol. Pathol. 37, 997-1005.
8. Davies, B., and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095.
9. Goldman, S. D., Funk, R. S., Rajewski, R. A., and Krise, J. P. (2009). Mechanisms of amine accumulation in, and egress from, lysosomes. Bioanalysis 1, 1445-1459.
10. Huang, L., Wang, Y., and Grimm, S. (2006). ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab. Dispos. 34, 738-742.
11. Jemnitz, K., Veres, Z., Tugyi, R., and Vereczkey, L. (2010). Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol. In Vitro 24, 605-610.
12. Joshi, U. M., Rao, P., Kodavanti, S., Lockard, V. G., and Mehendale, H. M. (1989). Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: Relevance to phospholipidosis. Biochim. Biophys. Acta 1004, 309-320.
13. Kaloyanides, G. J., and Pastoriza-Munoz, E. (1980). Aminoglycoside nephrotoxicity. Kidney Int. 18, 571-582.
14. Kazmi, F., Hensley, T., Pope, C., Funk, R. S., Loewen,G. J., Buckley,D. B., and Parkinson, A. (2013). Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab. Dispos. 41, 897-905.
15. Kitamura, S., Maeda, K., Wang, Y., and Sugiyama, Y. (2008). Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 36, 2014-2023.
16. LeCluyse, E. L., Bullock, P. L., Parkinson, A., and Hochman, J. H. (1996). Cultured rat hepatocytes. Pharm. Biotechnol. 8, 121-159.
17. LeCureux, L., Cheng, C. S., Herbst, J., Reilly, T. P., Lehman-McKeeman, L., and Otieno, M. (2011). Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential. Toxicol. In Vitro 25, 1934-1943.
18. Li, A. P. (1997). Primary hepatocyte cultures as an in vitro experimental model for the evaluation of pharmacokinetic drug-drug interactions. Adv. Pharmacol. 43, 103-130.
19. Liu, X., LeCluyse, E. L., Brouwer, K. R., Lightfoot, R. M., Lee, J. I., and Brouwer, K. L. R. (1999). Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J. Pharmacol. Exp. Ther. 289, 1592-1599.
20. Logan, R., Kong, A., and Krise, J. P. (2013). Evaluating the roles of autophagy and lysosomal trafficking defects in intracellular distribution-based drugdrug interactions involving lysosomes. J. Pharm. Sci. 102, 4173-4180.
21. Micromedex (2014). Micromedex Version 2.0, Thomson Reuters (Healthcare), Greenwood Village, Colo.
22. Ndolo, R. A., Forrest, M. L., and Krise, J. P. (2010). The role of lysosomes in limiting drug toxicity in mice. J. Pharmacol. Exp. Ther. 333, 120-128.
23. Ndolo, R. A., Jacobs, D. T., Forrest, M. L., and Krise, J. P. (2010). Intracellular distribution-based anticancer drug targeting: Exploiting a lysosomal acidification defect associated with cancer cells. Mol. Cell. Pharmacol. 2, 131-136.
24. Oikawa, H., Maesawa, C., Sato, R., Oikawa, K., Yamada, H., Oriso, S., Ono, S., Yashima-Abo, A., Kotani, K., Suzuki, K., et al. (2005). Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: A case report. World J. Gastroenterol. 11, 5394-5397.
25. Pelletier, D. J., Gehlhaar, D., Tilloy-Ellul, A., Johnson, T. O., and Greene, N. (2007). Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J. Chem. Inf. Model. 47, 1196-1205.
26. Pfeifer, N. D., Bridges, A. S., Ferslew, B. C., Hardwick, R. N., and Brouwer, K. L. R. (2013). Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: Characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. J. Pharmacol. Exp. Ther. 347, 737-745.
27. Pfeifer, N. D., Yang, K., and Brouwer, K. L. R. (2013). Hepatic basolateral efflux contributes significantly to rosuvastatin disposition. I. Characterization of basolateral versus biliary clearance using a novel protocol in sandwichcultured hepatocytes. J. Pharmacol. Exp. Ther. 347, 727-736.
28. Ploemen, J. P., Kelder, J., Hafmans, T., van de Sandt, H., van Burgsteden, J. A., Saleminki, P. J., and van Esch, E. (2004). Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: A case study with structurally related piperazines. Exp. Toxicol. Pathol. 55, 347-355.
29. Reasor,M. J., and Kacew, S. (1996). An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Proc. Soc. Exp. Biol. Med. 212, 297-304.
30. Reasor,M. J., Hastings, K. L., and Ulrich, R. G. (2006). Drug-induced phospholipidosis: Issues and future directions. Expert Opin. Drug Saf. 5, 567-583.
31. Reasor, M. J., Ogle, C. L., and Kacew, S. (1989). Amiodarone-induced pulmonary toxicity in rats: Biochemical and pharmacological characteristics. Toxicol. Appl. Pharmacol. 97, 124-133.
32. Ruben, Z., Dodd, D. C., Rorig, K. J., and Anderson, S. N. (1989). Disobutamide: A model agent for investigating intracellular drug storage. Toxicol. Appl. Pharmacol. 97(1), 57-71.
33. Schwarz, L. R., Burr, R., Schwenk, M., Pfaff, E., and Greim, H. (1975). Uptake of taurocholic acid into isolated rat-liver cells. Eur. J. Biochem. 55, 617-623.
34. Shahane, S. A., Huang, R., Gerhold, D., Baxa, U., Austin, C. P., and Xia, M. (2013). Detection of phospholipidosis induction: A cell-based assay in highthroughput and high-content format. J. Biomol. Screen. 19, 66-76.
35. Sun, H., Xia, M., Shahane, S. A., Jadhav, A., Austin, C. P., and Huang, R. (2013). Are hERG channel blockers also phospholipidosis inducers? Bioorg. Med. Chem. Lett. 23, 4587-4590.
36. Swift, B., Pfeifer, N. D., and Brouwer, K. L. R. (2010). Sandwich-cultured hepatocytes: An in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab. Rev. 42, 446-471.
37. Trauner, M., and Boyer, J. L. (2003). Bile salt transporters: Molecular characterization, function, and regulation. Physiol. Rev. 83, 633-671.
38. Vitovic, P., Alakoskela, J. M., and Kinnunen, P. K. (2008). Assessment of druglipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis. J. Med. Chem. 51, 1842-1848.
39. Xia, M., Shahane, S. A., Huang, R., Titus, S. A., Shum, E., Zhao, Y., Southall, N., Zheng, W.,Witt, K. L., Tice, R. R., et al. (2011). Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicol. Appl. Pharmacol. 252, 250-258.
40. Zheng, N., Zhang, X., and Rosania, G. R. (2011). Effect of phospholipidosis on the cellular pharmacokinetics of chloroquine. J. Pharmacol. Exp. Ther. 336, 661-671.
41. Zhou, L., Geraci, G., Hess, S., Yang, L.,Wang, J., and Argikar, U. (2011). Predicting phospholipidosis: A fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery. Anal. Chem. 83, 6980-6987.